Artiva Biotherapeutics公司公布的最新初步研究数据显示，在针对难治性类风湿关节炎患者的临床试验中，接受治疗六个月后达到ACR50应答标准的患者比例高达71%。这一积极数据展现了该公司在细胞疗法领域的研发潜力。
ACR50是评估类风湿关节炎治疗效果的权威指标，代表患者症状和身体功能至少改善50%。对于现有疗法反应不佳的难治性患者群体而言，达到如此高比例的应答率具有重要临床意义。
Artiva Biotherapeutics公司公布的最新初步研究数据显示，在针对难治性类风湿关节炎患者的临床试验中，接受治疗六个月后达到ACR50应答标准的患者比例高达71%。这一积极数据展现了该公司在细胞疗法领域的研发潜力。
ACR50是评估类风湿关节炎治疗效果的权威指标，代表患者症状和身体功能至少改善50%。对于现有疗法反应不佳的难治性患者群体而言，达到如此高比例的应答率具有重要临床意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.